Outlook Therapeutics (NASDAQ:OTLK – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at BTIG Research in a research note issued to investors on Friday, Benzinga reports. They presently have a $50.00 target price on the stock.
Several other analysts have also weighed in on the stock. Ascendiant Capital Markets decreased their target price on shares of Outlook Therapeutics from $35.00 to $33.00 and set a “buy” rating on the stock in a research report on Tuesday, September 3rd. Chardan Capital restated a “buy” rating and issued a $53.00 price target on shares of Outlook Therapeutics in a research report on Friday, August 16th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Outlook Therapeutics in a report on Thursday, August 15th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $48.20.
Get Our Latest Stock Report on Outlook Therapeutics
Outlook Therapeutics Stock Performance
Outlook Therapeutics (NASDAQ:OTLK – Get Free Report) last issued its earnings results on Wednesday, August 14th. The company reported ($0.83) EPS for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.23. On average, equities research analysts predict that Outlook Therapeutics will post -3.63 EPS for the current year.
Insiders Place Their Bets
In other news, CFO Lawrence A. Kenyon bought 5,000 shares of the stock in a transaction dated Thursday, September 26th. The stock was bought at an average cost of $5.69 per share, with a total value of $28,450.00. Following the purchase, the chief financial officer now owns 5,946 shares of the company’s stock, valued at approximately $33,832.74. This represents a 500.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 3.40% of the company’s stock.
Institutional Investors Weigh In On Outlook Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of the business. Great Point Partners LLC raised its position in shares of Outlook Therapeutics by 15.0% during the 2nd quarter. Great Point Partners LLC now owns 1,701,510 shares of the company’s stock valued at $12,557,000 after acquiring an additional 221,510 shares during the last quarter. Rosalind Advisors Inc. boosted its position in shares of Outlook Therapeutics by 44.3% during the second quarter. Rosalind Advisors Inc. now owns 450,000 shares of the company’s stock worth $3,321,000 after purchasing an additional 138,225 shares in the last quarter. LVW Advisors LLC bought a new position in shares of Outlook Therapeutics during the second quarter worth $352,000. Susquehanna Fundamental Investments LLC bought a new stake in shares of Outlook Therapeutics in the 2nd quarter valued at $303,000. Finally, Squarepoint Ops LLC acquired a new stake in Outlook Therapeutics during the 2nd quarter worth $232,000. 11.20% of the stock is owned by institutional investors.
About Outlook Therapeutics
Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Read More
- Five stocks we like better than Outlook Therapeutics
- How to Use the MarketBeat Dividend Calculator
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- Learn Technical Analysis Skills to Master the Stock Market
- Analysts See Growth in CrowdStrike Stock Despite July Setback
- Quiet Period Expirations Explained
- The Uptrend in Netflix Will Continue: Another 15% Upside Ahead
Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.